Luspatercept for CIA in AML
Efficacy and Safety of Luspatercept in Treating Chemotherapy-inducing Anemia in Acute Myeloid Leukemia: a Multicenter, Prospective, Single-arm Study
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Guopan Yu, PhD
- Telefonnummer: +8615876559968
- E-mail: yugpp@163.com
Undersøgelse Kontakt Backup
- Navn: Tianmiao Yu, Master
- E-mail: yutm96@163.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- Department of Hematology, Guangdong Second Provincial General Hospital
-
Kontakt:
- Guopan Yu, PhD
- Telefonnummer: +8615876559968
- E-mail: yugpp@163.com
-
Kontakt:
- Tianmiao Yu, Master
- E-mail: yutm96@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- De novo AML patients;
- Age ≥ 18 years and ≤ 60 years;
- AML with ELN2022-low risk
- Received 1-3 cycles of HDAC consolidation therapy
- HGB 60-90 G/L
- Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points;
- Life expectancy ≥ 3 months;
- Signed informed consent and able to understand and comply with the procedures required by this protocol.
Exclusion Criteria:
- t-AML/sAML
- Concurrent myelofibrosis
- Patients unresponsive to red blood cell transfusions
- Heart function < grade 2
- Renal function: creatinine clearance < 30 ml/min
- Liver function: ALTd > 5 times normal, bilirubin > 3 times normal
- Uncontrolled hypertension, defined as recurrent elevations in diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment
- History of stroke, deep vein thrombosis (DVT), pulmonary or arterial embolism within 6 months prior to randomization
- Uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent infection-related signs/symptoms that do not improve despite appropriate antibiotic, antiviral, and/or other treatments), known human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection, and/or hepatitis C. (HCV) infection
- History of severe allergy or allergic reaction to recombinant proteins, or allergy to rotezip or excipients
- Pregnant or breastfeeding women
- Patients deemed unsuitable for enrollment by the investigators
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Rotesip treatment group
Patients were screened and enrolled in the treatment group to evaluate the efficacy and safety of rotezipeptide in the treatment of chemotherapy-inducing anemia in AML.
|
First, enrolled patients were randomized to received rotezipeptide with a dosage of 1mg/kg at the day 1 versus day 10 post chemotherapy.
Each groups were analyzed to enroll et least 10 patients.
Second, after working out which day should be the better one for the treatment of rotezipeptide in phase 1 study, at least 20 patients were enrolled to received rotezipeptide with the same dose at the above day to further work out the efficacy and safety of rotezipeptide in the treatment of CIA in AML.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time of 50% increase in hemoglobin levels from baseline
Tidsramme: Days 1-28 post chemotherapy
|
The time of hemoglobin levels increasing 50% from baseline
|
Days 1-28 post chemotherapy
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of HGB < 60 G/L during the treatment course (1-28 days)
Tidsramme: Days 1-28 after AML chemistry treatment
|
The duration of HGB < 60 G/L during this consolidation treatment course (days 1-28);
|
Days 1-28 after AML chemistry treatment
|
|
Incidence of HGB < 60 G/L during the treatment course (days 1-28)
Tidsramme: Days 1-28 after chemotherapy
|
The incidence of HGB < 60 G/L during this consolidation treatment course (days 1-28);
|
Days 1-28 after chemotherapy
|
|
Red blood cell transfusion volume
Tidsramme: Days 1-28 after AML chemistry treamtment
|
Red blood cell transfusion volume during this consolidation treatment course (days 1-28);
|
Days 1-28 after AML chemistry treamtment
|
|
MRD negative rate
Tidsramme: 6 months after AML chemistry treamtment
|
MRD negative rate within 6 months;
|
6 months after AML chemistry treamtment
|
|
Anemia recurrence rate
Tidsramme: 12 months after AML chemistry treamtment
|
Relapse rate 12 months after chemotherapy;
|
12 months after AML chemistry treamtment
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of people experiencing treatment-related adverse events
Tidsramme: Days 1-28 after Luspatercept treatment
|
According to the CTCAE v5.0 assessment, the number of people who experienced treatment-related adverse events included both hematological and non-hematological toxicities.
|
Days 1-28 after Luspatercept treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GD2H-2026-483
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .